• Markets
    • icon
  • Companies
CUV · ASX

Clinuvel Pharmaceuticals Limited (ASX:CUV)

AU$14.98

 0.0 (0.0%)
ASX:Live
26/07/2024 04:10:15 PM
Hammer Bullish HALO Small HALO Ords HALO Capital Efficiency HALO Balance Sheet +5
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CUV Overview

CUV Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Neutral

GARP

Neutral

MQV Small

Strong

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Neutral

Growth

Earnings

Strong

Dividends

Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About CUV

Website

Clinuvel Pharmaceuticals Limited

Telephone

61.3.9660.4900

Address

Level 11 535 Bourke Street Melbourne, Victoria (VIC) 3000

Description

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

CUV Price Chart

Key Stats

Market Cap

AU$756.17M

PE

34.60

EV/EBITDA

21.7

Dividends Overview

DIV Yield

.3%

Franking

100%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 12.96 - 21.45

Trade Value (12mth)

AU$372,621.00

1 week

-3.54%

1 month

-2.6%

YTD

-7.87%

1 year

-20.19%

All time high

45.88

Key Fundamentals

EPS 3 yr Growth

102.700%

EBITDA Margin

53.20%

Operating Cashflow

$37m

Free Cash Flow Return

25.30%

ROIC

21.00%

Interest Coverage

N/A

Quick Ratio

7.10

Other Data

Shares on Issue (Fully Dilluted)

52m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

5.79

CUV Announcements

Latest Announcements

Date Announcements

05 July 24

Afamelanotide Assists DNA Repair Response Following UVR

×

Afamelanotide Assists DNA Repair Response Following UVR

05 July 24

Notification of cessation of securities - CUV

×

Notification of cessation of securities - CUV

28 June 24

Change of Company Secretary

×

Change of Company Secretary

28 June 24

CLINUVEL extends Managing Director Employment Agreement

×

CLINUVEL extends Managing Director Employment Agreement

24 June 24

SCENESSE European Orphan Drug Designation for VP

×

SCENESSE European Orphan Drug Designation for VP

18 June 24

afamelanotide in fair-skinned Parkinsons patients

×

afamelanotide in fair-skinned Parkinsons patients

11 June 24

CLINUVEL Newsletter III - June 2024

×

CLINUVEL Newsletter III - June 2024

05 June 24

Update - Notification of buy-back - CUV

×

Update - Notification of buy-back - CUV

03 June 24

CLINUVEL withdraws label expansion for adolescent EPP

×

CLINUVEL withdraws label expansion for adolescent EPP

24 May 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

23 May 24

CLINUVEL and Valentech enter Latin American partnership

×

CLINUVEL and Valentech enter Latin American partnership

14 May 24

Becoming a substantial holder

×

Becoming a substantial holder

14 May 24

Update - Notification of buy-back - CUV

×

Update - Notification of buy-back - CUV

10 May 24

Update - Notification of buy-back - CUV

×

Update - Notification of buy-back - CUV

09 May 24

Update - Notification of buy-back - CUV

×

Update - Notification of buy-back - CUV

06 May 24

Update - Notification of buy-back - CUV

×

Update - Notification of buy-back - CUV

03 May 24

Update - Notification of buy-back - CUV

×

Update - Notification of buy-back - CUV

01 May 24

Syd Capital Markets Briefing Presentation

×

Syd Capital Markets Briefing Presentation

29 April 24

Update - Notification of buy-back - CUV

×

Update - Notification of buy-back - CUV

29 April 24

Notification of cessation of securities - CUV

×

Notification of cessation of securities - CUV

29 April 24

SCENESSE European Orphan Drug Designation for XP

×

SCENESSE European Orphan Drug Designation for XP

26 April 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

22 April 24

CLINUVEL expands global leadership team

×

CLINUVEL expands global leadership team

15 April 24

Change to executive management

×

Change to executive management

12 April 24

Update - Notification of buy-back - CUV

×

Update - Notification of buy-back - CUV

CUV Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock 0.50 0.42 0.62 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock 0.48 0.40 0.59 Lock Lock Lock
     Growth % Lock Lock Lock Lock 63.8 -15.6 46.6 Lock Lock Lock
     PE X Lock Lock Lock Lock 75.1 42.7 34.6 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 62.7 24.7 21.7 Lock Lock Lock
CFPS $ Lock Lock Lock Lock 0.62 0.69 0.81 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock 0.34 0.74 0.65 Lock Lock Lock
     Growth % Lock Lock Lock Lock 148.0 10.8 18.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock 1.1 5.0 3.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.02 0.04 0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.0 60.0 25.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.1 0.1 0.3 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 5 9 8 Lock Lock Lock
BPS $ Lock Lock Lock Lock 2.00 2.54 3.33 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 1.99 2.54 3.33 Lock Lock Lock
     Growth % Lock Lock Lock Lock 37.1 27.2 31.2 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 51 52 52 Lock Lock Lock
Basic m Lock Lock Lock Lock 49 49 49 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 48 66 78 Lock Lock Lock
     Growth % Lock Lock Lock Lock 47.3 37.0 19.2 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 9 14 10 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 35 47 51 Lock Lock Lock
     Growth % Lock Lock Lock Lock 91.0 32.4 8.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock 73.4 70.9 64.6 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 27 29 35 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock 28 34 42 Lock Lock Lock
     Growth % Lock Lock Lock Lock 158.9 22.8 23.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock 57.4 51.5 53.2 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock 27 33 41 Lock Lock Lock
     Growth % Lock Lock Lock Lock 161.8 23.9 23.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock 55.6 50.3 52.2 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock 26 34 46 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 1 13 15 Lock Lock Lock
Net Income $m Lock Lock Lock Lock 25 21 31 Lock Lock Lock
     Growth % Lock Lock Lock Lock 64.3 -15.6 46.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock 51.5 31.8 39.1 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock 19 40 37 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 0 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 0 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock -1 -2 -2 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock 18 39 36 Lock Lock Lock
     Growth % Lock Lock Lock Lock 38.4 114.2 -9.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.4 0.6 0.5 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 1 N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 83 122 157 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 109 145 195 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -81 -120 -156 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 10 19 30 Lock Lock Lock
Equity $m Lock Lock Lock Lock 99 126 165 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 100 127 165 Lock Lock Lock
     Growth % Lock Lock Lock Lock 36.4 26.8 30.7 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock 22.8 14.4 15.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 25.0 16.6 18.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock 30.5 29.2 28.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock 28.3 18.5 21.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock 22.1 35.2 25.3 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -3.0 -3.6 -3.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -82.4 -95.8 -94.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 11.8 10.2 7.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 11.4 10.1 7.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 80.4 86.4 82.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock 221.2 290.4 144.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 4.2 4.1 4.1 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 5.7 7.6 4.9 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.5 0.5 0.5 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 4.8 0.4 3.6 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.4 0.5 0.4 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.4 0.5 0.4 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 53.6 52.2 58.2 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 23.7 23.7 23.4 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 3.8 39.2 32.9 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock 22.8 14.4 15.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.2 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 25.0 16.6 18.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 95.0 90.5 91.9 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock 23.8 15.1 17.1 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 63.9 47.9 74.7 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 86.4 89.7 89.5 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 150.3 137.6 164.2 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 46.7 26.6 15.7 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 103.6 111.1 148.5 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.3%

Franking Level

100%

DPSg

25.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Expected Dividend Cashflow

Dividend Clarity,
Enhanced
Strategy

Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

5.79%

Value ($M)

45

Prior Change

0.20%

7 Day Change

N/A

1 Month Change

-0.10%

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CUV Shortsell

Frequently Asked Questions

The current share price of Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$14.98.
The 52-week high share price for Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$21.45.
The 52-week low share price for Clinuvel Pharmaceuticals Limited (CUV:ASX)? is AU$12.96.
The current TTM dividend payout for Clinuvel Pharmaceuticals Limited (CUV:ASX) is 0.30.
The last dividend payment of Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$0.05.
Clinuvel Pharmaceuticals Limited (CUV:ASX) has a franking level of 100.0%.
Clinuvel Pharmaceuticals Limited (CUV:ASX) is classified in the Healthcare.
The current P/E ratio for Clinuvel Pharmaceuticals Limited (CUV:ASX) is 34.60.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.